Skip to main content

Table 2 Demographic and clinical features of the MSA patients with and without camptocormia according to different disease durations

From: Camptocormia in patients with multiple system atrophy at different disease durations: frequency and related factors

Variables

Disease duration ≤3 years

Disease duration 3–5 years

Disease duration ≥5 years

With camptocormia

Without camptocormia

P value

With camptocormia

Without camptocormia

P value

With camptocormia

Without camptocormia

P value

Number

42 (8.9%)

428 (91.1%)

–

34 (19.7%)

139 (80.3%)

–

14 (19.2%)

59 (80.8%)

–

Diagnosis (MSA-P/MSA-C)

26/16

185/243

0.020*

23/11

76/63

0.171

11/3

31/28

0.077

Sex (male/female)

17/25

238/190

0.060

20/14

81/58

0.953

9/5

40/19

0.802

Age

63.23 ± 7.94

58.65 ± 8.50

0.001*

63.79 ± 8.48

62.50 ± 9.65

0.539

65.11 ± 6.49

60.40 ± 9.87

0.073

Age of onset

61.38 ± 7.87

56.99 ± 8.51

0.001*

60.02 ± 8.17

58.72 ± 9.65

0.595

59.19 ± 6.96

54.27 ± 10.31

0.062

Disease duration

1.83 ± 0.74

1.59 ± 0.73

0.040

3.68 ± 0.58

3.76 ± 0.62

0.614

6.02 ± 1.13

6.14 ± 1.36

0.861

Educational year

9.38 ± 4.13

9.49 ± 3.90

0.809

9.03 ± 4.28

9.36 ± 3.71

0.523

9.14 ± 4.24

9.86 ± 4.29

0.572

Onset symptoms

         

Autonomic symptom

13

134

0.094

10

58

0.146

5

27

0.608

Cerebellar symptom

8

143

5

29

2

11

Parkinsonism symptom

21

151

19

52

7

21

UMSARS-I

16.64 ± 6.28

12.35 ± 5.97

< 0.001*#

17.94 ± 7.33

16.54 ± 5.88

0.340

22.00 ± 9.72

17.56 ± 6.93

0.157

UMSARS-II

20.79 ± 6.85

15.15 ± 6.33

< 0.001*#

21.53 ± 8.18

18.72 ± 5.94

0.142

26.07 ± 7.36

18.66 ± 7.49

0.003*

UMSARS-IV

2.52 ± 1.04

1.72 ± 0.74

< 0.001*#

2.68 ± 1.17

2.22 ± 1.01

0.036

3.14 ± 1.46

2.46 ± 1.07

0.093

Total UMSARS score

37.43 ± 12.10

27.50 ± 11.41

< 0.001 *#

39.47 ± 14.93

35.26 ± 10.85

0.207

48.07 ± 16.31

36.22 ± 13.74

0.027

OH (yes/no)

10/32

107/321

0.865

13/21

43/96

0.415

5/9

20/39

1.000

Total score of FAB

12.81 ± 3.80

14.49 ± 2.93

0.007*

14.18 ± 2.71

14.22 ± 2.65

0.962

14.07 ± 3.85

14.56 ± 2.91

0.843

Total MOCA score

20.05 ± 6.51

21.79 ± 4.95

0.197

21.88 ± 4.99

21.36 ± 4.74

0.568

19.86 ± 6.60

21.81 ± 5.03

0.500

HDRS score

13.14 ± 7.86

10.39 ± 7.68

0.025*

13.24 ± 9.63

12.10 ± 7.57

0.748

15.64 ± 11.41

14.54 ± 8.43

0.972

HARS score

9.71 ± 6.63

8.69 ± 6.71

0.256

9.32 ± 7.65

10.75 ± 7.15

0.163

13.21 ± 7.91

11.73 ± 7.69

0.457

LEDD (mg/day)

135.12 ± 240.37

97.52 ± 204.27

0.347

256.61 ± 263.95

185.07 ± 262.41

0.070

318 ± 324.44

204.24 ± 338.86

0.118

  1. MSA multiple system atrophy, MSA-P multiple system atrophy with predominately parkinsonism, MSA-C multiple system atrophy with predominately cerebellar ataxia, UMSARS unified multiple system atrophy rating scale, OH orthostatic hypotension, FAB frontal lobe battery, MoCA Montreal cognitive assessment, HDRS Hamilton depression rating scale, HARS Hamilton anxiety rating scale, LEDD levodopa equivalent daily dose
  2. *: significant difference after adjusting by false discovery rate
  3. #: after adjusting for age of onset and disease duration
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us